NEUROGENE INC
NGNENASDAQTrading Snapshot
- Day Range
- $28.14 – $28.75
- 52-Week Range
- $15.93 – $43.66
- Volume
- $2.63B
- Avg Volume
- $3.10B
- Shares Outstanding
- 19.7M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $137M
- Last Q Revenue
- $33M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.16
- Dividend Yield
- —
- Dilution (1yr)
- +4.3%
Why Investors Own NGNE
- ✓High-growth profile — revenue up +38.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NEUROGENE INC
NGNE
StockOtter · stockotter.spaceAbout NEUROGENE INC
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Head-To-Head Comparison: Neurogene (NASDAQ:NGNE) & Applied Dna Sciences (NASDAQ:BNBX)
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based o
Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNE
Bank of New York Mellon Corp acquired a new position in shares of Neurogene Inc. (NASDAQ: NGNE) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange C
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Co
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that th
BlackRock Inc. Invests $33.27 Million in Neurogene Inc. $NGNE
BlackRock Inc. acquired a new position in shares of Neurogene Inc. (NASDAQ: NGNE) in the undefined quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,057,983 shares of the company's stock,
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological